A Phase 1 interventional study of Sitagliptin/metformin XR and Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-10-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 155th largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 23 in phase 1, and was the 114th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 16 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 140th largest by enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2012, is one of 55 in phase 1, and was the 127th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Day 1 (Period 1): participants will receive a single dose of two sitagliptin/metformin XR tablets with a low- to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
Drug: Sitagliptin/metformin XR · Drug: Placebo · Drug: Metformin · Drug: Thyroid hormone
Days 1-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
Drug: Placebo · Drug: Metformin · Drug: Thyroid hormone
Drug pages: Sitagliptin · Metformin
Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metformin XR 2000 mg).
Also known as: MK-0431A XR, Janumet XR
Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
Number of Participants Who Successfully Swallowed Study Medication (Med) on Day 2
The Swallowing Ability Questionnaire was completed on Day 2 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.
Time frame: Day 2
Number of Participants Who Successfully Swallowed Study Med on Day 4
The Swallowing Ability Questionnaire was completed on Day 4 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.
Time frame: Day 4
Number of Participants Who Successfully Swallowed Study Med on Day 6
The Swallowing Ability Questionnaire was completed on Day 6 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.
Time frame: Day 6
Number of Participants Who Successfully Swallowed Study Med on Day 9
The Swallowing Ability Questionnaire was completed on Day 9 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.
Time frame: Day 9
Area Under the Curve 0 to Last (AUC 0-last) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR
In this study, metformin products were withheld 24 hours (hrs) prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hrs post study drug administration. Owing to resumption of therapeutic metformin administration 24 hrs after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax) and area under the curve 0 to 24 hrs (AUC0-24hr). Therefore, metformin arm is not included in this endpoint.
Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
AUC 0-24 of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR
Due different units of measure for sitagliptin and metformin, metformin data are presented in another endpoint.
Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours post-dose
AUC 0-24 of Metformin Following Single Administration of Sitagliptin/Metformin XR
In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Due different units of measure for sitagliptin and metformin, sitagliptin data are presented in another endpoint.
Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours post-dose
Area Under the Curve 0 to Infinity (AUC 0-∞) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR
In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Owing to resumption of therapeutic metformin administration 24 hours after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to Cmax, Tmax and AUC0-24hr. Therefore, metformin arm is not included in this endpoint.
Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
Cmax of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR
Due different units of measure for sitagliptin and metformin, metformin data are presented in another endpoint.
Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
Cmax of Metformin Following Single Dose Administration of Sitagliptin/Metformin XR
In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Due different units of measure for sitagliptin and metformin, sitagliptin data are presented in another endpoint.
Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
Tmax of Sitagliptin and Metformin Following Single Dose Administration of Sitagliptin/Metformin XR
In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration.
Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
Apparent Terminal Half Life (t1/2) of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR
In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Owing to resumption of therapeutic metformin administration 24 hours after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to Cmax, Tmax and AUC0-24hr. Therefore, metformin arm is not included in this endpoint.
Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
Number of Participants Who Experienced an Adverse Event (AE)
An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.
Time frame: Up to 23 days (including approximately 10 to 14 days after the last dose of study drug)
Number of Participants Who Experienced an Abnormal Vital Sign Value
Vital sign measurements included blood pressure, heart rate, respiratory rate, and oral temperature.
Time frame: Up to 23 days (including approximately 10 to 14 days after the last dose of study drug)
Number of Participants Who Discontinued Study Drug Due to an AE
An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an IMP, regardless of causal relationship and even if no IMP has been administered.
Time frame: Up to 9 days
| Milestone | Sitagliptin/Metformin XR Followed by Placebo | Placebo |
|---|---|---|
| Started | 13 | 12 |
| Completed | 12 | 12 |
| Not completed | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
The Swallowing Ability Questionnaire was completed on Day 2 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.
| Participants | All Treated Participants |
|---|---|
| Strongly Agreed: Could Only Swallow Med With Help | 6 |
| Agreed: Could Only Swallow Med With Help | 7 |
| Strongly Agreed: Easy to Start Swallowing Med | 10 |
| Agreed: Easy to Start Swallowing Med | 12 |
| Strongly Agreed: Easy to Swallow Med | 13 |
| Agreed: Easy to Swallow Med | 10 |
| Strongly Agreed: Felt Like Med Got Stuck in Throat | 0 |
| Agreed: Felt Like Med Got Stuck in Throat | 4 |
| Strongly Agreed: Had to Swallow Med More Than Once | 2 |
| Agreed: Had to Swallow Med More Than Once | 3 |
The Swallowing Ability Questionnaire was completed on Day 4 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.
| Participants | All Treated Participants |
|---|---|
| Strongly Agreed: Could Only Swallow Med With Help | 6 |
| Agreed: Could Only Swallow Med With Help | 6 |
| Strongly Agreed: Easy to Start Swallowing Med | 8 |
| Agreed: Easy to Start Swallowing Med | 14 |
| Strongly Agreed: Easy to Swallow Med | 8 |
| Agreed: Easy to Swallow Med | 15 |
| Strongly Agreed: Felt Like Med Got Stuck in Throat | 0 |
| Agreed: Felt Like Med Got Stuck in Throat | 4 |
| Strongly Agreed: Had to Swallow Med More Than Once | 0 |
| Agreed: Had to Swallow Med More Than Once | 5 |
The Swallowing Ability Questionnaire was completed on Day 6 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.
| Participants | All Treated Participants |
|---|---|
| Strongly Agreed: Could Only Swallow Med With Help | 5 |
| Agreed: Could Only Swallow Med With Help | 7 |
| Strongly Agreed: Easy to Start Swallowing Med | 10 |
| Agreed: Easy to Start Swallowing Med | 11 |
| Strongly Agreed: Easy to Swallow Med | 11 |
| Agreed: Easy to Swallow Med | 12 |
| Strongly Agreed: Felt Like Med Got Stuck in Throat | 0 |
| Agreed: Felt Like Med Got Stuck in Throat | 3 |
| Strongly Agreed: Had to Swallow Med More Than Once | 2 |
| Agreed: Had to Swallow Med More Than Once | 5 |
The Swallowing Ability Questionnaire was completed on Day 9 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.
| Participants | All Treated Participants |
|---|---|
| Strongly Agreed: Could Only Swallow Med With Help | 9 |
| Agreed: Could Only Swallow Med With Help | 5 |
| Strongly Agreed: Easy to Start Swallowing Med | 9 |
| Agreed: Easy to Start Swallowing Med | 13 |
| Strongly Agreed: Easy to Swallow Med | 12 |
| Agreed: Easy to Swallow Med | 11 |
| Strongly Agreed: Felt Like Med Got Stuck in Throat | 1 |
| Agreed: Felt Like Med Got Stuck in Throat | 1 |
| Strongly Agreed: Had to Swallow Med More Than Once | 2 |
| Agreed: Had to Swallow Med More Than Once | 5 |
In this study, metformin products were withheld 24 hours (hrs) prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hrs post study drug administration. Owing to resumption of therapeutic metformin administration 24 hrs after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax) and area under the curve 0 to 24 hrs (AUC0-24hr). Therefore, metformin arm is not included in this endpoint.
| nM*hr/mL | Sitagliptin |
|---|---|
| Area Under the Curve 0 to Last (AUC 0-last) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR | 5940 ± 25.7 |
Due different units of measure for sitagliptin and metformin, metformin data are presented in another endpoint.
| nM*hr | Sitagliptin |
|---|---|
| AUC 0-24 of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR | 5310 ± 22.4 |
In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Due different units of measure for sitagliptin and metformin, sitagliptin data are presented in another endpoint.
| ng*hr/mL | Metformin |
|---|---|
| AUC 0-24 of Metformin Following Single Administration of Sitagliptin/Metformin XR | 14200 ± 39.7 |
In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Owing to resumption of therapeutic metformin administration 24 hours after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to Cmax, Tmax and AUC0-24hr. Therefore, metformin arm is not included in this endpoint.
| nM*hr | Sitagliptin |
|---|---|
| Area Under the Curve 0 to Infinity (AUC 0-∞) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR | 6020 ± 24.8 |
Due different units of measure for sitagliptin and metformin, metformin data are presented in another endpoint.
| nM | Sitagliptin |
|---|---|
| Cmax of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR | 757 ± 40.1 |
In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Due different units of measure for sitagliptin and metformin, sitagliptin data are presented in another endpoint.
| ng/mL | Metformin |
|---|---|
| Cmax of Metformin Following Single Dose Administration of Sitagliptin/Metformin XR | 1490 ± 29.1 |
In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration.
| Hour | Sitagliptin | Metformin |
|---|---|---|
| Tmax of Sitagliptin and Metformin Following Single Dose Administration of Sitagliptin/Metformin XR | 1.52 (0.97 to 3.05) | 5.00 (3.98 to 7.22) |
In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Owing to resumption of therapeutic metformin administration 24 hours after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to Cmax, Tmax and AUC0-24hr. Therefore, metformin arm is not included in this endpoint.
| Hour | Sitagliptin |
|---|---|
| Apparent Terminal Half Life (t1/2) of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR | 10.0 ± 27.3 |
An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.
| Participants | Sitagliptin | Placebo |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 5 | 5 |
Vital sign measurements included blood pressure, heart rate, respiratory rate, and oral temperature.
| Participants | Sitagliptin | Placebo |
|---|---|---|
| Number of Participants Who Experienced an Abnormal Vital Sign Value | 0 | 0 |
An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an IMP, regardless of causal relationship and even if no IMP has been administered.
| Participants | Sitagliptin | Placebo |
|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an AE | 0 | 0 |
Collected over Up to 23 days (including approximately 10 to 14 days after the last dose of study drug). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin/Metformin XR Followed by Placebo | — | 0/13 (0%) | 5/13 (38.5%) |
| Placebo | — | 0/12 (0%) | 5/12 (41.7%) |
| Event | Sitagliptin/Metformin XR Followed by Placebo | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 1/13 | 1/12 |
| Upper respiratory tract infectionInfections and infestations | 0/13 | 1/12 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/13 | 1/12 |
| Plantar fasciitisMusculoskeletal and connective tissue disorders | 0/13 | 1/12 |
| Vulvovaginal pruritusReproductive system and breast disorders | 0/13 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 1/13 | 0/12 |
| VomitingGastrointestinal disorders | 1/13 | 0/12 |
| Seasonal allergyImmune system disorders | 1/13 | 0/12 |
| Urine analysis abnormalInvestigations | 1/13 | 0/12 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/13 | 0/12 |
| Age, Customized(Participants) | Sitagliptin/Metformin XR Followed by Placebo | Placebo | Total |
|---|---|---|---|
| 10-13 years | 4 | 3 | 7 |
| 14-17 years | 9 | 9 | 18 |
| Sex: Female, Male(Participants) | Sitagliptin/Metformin XR Followed by Placebo | Placebo | Total |
|---|---|---|---|
| Female | 9 | 8 | 17 |
| Male | 4 | 4 | 8 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from Jul 2012 to primary completion in Apr 2014, 21 months.
Results were first posted in May 2015, 1 year after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 21 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Metformin